Disclosure of updates to development plans centered on the glaucoma treatment H-1337. Provides progress of the development pipeline and upcoming clinical trial plans. Presents region-by-region development items and future regulatory submission schedules.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4576","jir_company_name":"D. Western Therapeutics Institute, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4576-20260903-02.pdf","jir_short_summary":"Disclosure of updates to development plans centered on the glaucoma treatment H-1337. Provides progress of the development pipeline and upcoming clinical trial plans. Presents region-by-region development items and future regulatory submission schedules.","jir_summary":"### Section Heading\nThis update communicates updates to development pipeline progress plans and status of clinical trial applications and approvals, focusing on the glaucoma treatment product centered on H-1337 and other development products. Development schedule includes updates to the start timing of Phase 3, with favorable results in Phase 2b, and a policy prioritizing development in Japan. Regional development products are described for Japan, the United States, China, etc., with expectations for future submissions and approvals. Overall, this update includes development plans with license-out considerations, and provides reference for development risks and progress charts.\n\n### Section 2 Heading\nFor shareholders and investors, progress of the development pipeline and the schedule for clinical trial approval submissions are important information. The update indicates small-dose confirmation trials starting in 2029, and the future progress of clinical trials and the overall pipeline roadmap are expected to be of high importance. This document describes regional progress, assumptions of development plans, and policy for disclosure as soon as confirmations are made, providing materials for evaluating development risk and opportunities in investment decisions.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#NoShareBuyback, #NoExecutiveChanges","jir_key_figures":"H-1337 development plan (Japan): progress of clinical trials and anticipated approvals\nH-1129 ocular surface disease based on immune dysregulation (Japan): development plan\nDW-5LBT postherpetic neuralgia (United States): development plan","jir_meta_title":"\u3010D. Western Therapeutics Institute, Inc.\u3011Business Plan Update | Development Pipeline Progress","jir_meta_description":"Updates to the development pipeline centered on the glaucoma treatment agent H-1337 and progress of clinical trial planning. Describes development status in Japan, the United States, and China and future regulatory submission schedules.","jir_og_title":"\u3010\u65e5 Western SerapItix Research Institute\u3011Development Pipeline Update","jir_og_description":"Announcement of updates to development plans centered on glaucoma treatment. Explains progress of clinical trials and outlook for approvals.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59943,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-110562","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n